José Juan
García Marín
Catedrático de Universidad
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (27)
2024
-
New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Impact of alternative splicing variants on liver cancer biology
Cancers, Vol. 14, Núm. 1
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology, Vol. 73, Núm. 6, pp. 2380-2396
-
Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis
Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221
2020
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
-
Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach
Cancers, Vol. 12, Núm. 6, pp. 1-30
2019
-
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Hepatology, Vol. 70, Núm. 2, pp. 547-562
-
The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis
Hepatology, Vol. 69, Núm. 4, pp. 1632-1647
2018
-
MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
Hepatology, Vol. 67, Núm. 4, pp. 1420-1440
-
Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib
Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485
-
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477